81 results on '"OVERALL survival"'
Search Results
2. Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC.
3. Impactful Studies Challenge the Status Quo at GI Conference.
4. Novel Approaches Focus on Limiting Toxicity in Older Patients with ALL.
5. 2023 World Conference on Lung Cancer.
6. 2023 ASCO Genitourinary Cancers Symposium Data at a Glance.
7. Expanding 177Lutetium-PSMA-617 Use in the Community.
8. The Benefits of Elacestrant in HR+/HER2– Metastatic Breast Cancer Subgroups.
9. Clinical Updates: KIDNEY CANCER. Updated data show OS benefit with adjuvant pembrolizumab in ccRCC.
10. From the Co-Editor in Chief: BCG-unresponsive NMIBC: Advancements are moving the needle.
11. Abemaciclib, NSAI Extend Overall Survival for Patients With Hormone Receptor--Positive, HER2-Negative Advanced Breast Cancer.
12. Survival Outcomes and PROs Favor Cemiplimab + Chemotherapy vs Chemotherapy Alone in Advanced NSCLC Regardless of PD-L1 Status.
13. Induction Chemotherapy Prior to Chemoradiation Represents Potential New SOC in Locally Advanced Cervical Cancer.
14. Clinical Updates: PROSTATE CANCER. Darolutamide delays time to progression from mHSPC to mCRPC vs placebo.
15. Clinical Updates: PROSTATE CANCER. Survival may be improving in de novo mHSPC, new data suggest.
16. Clinical Updates: BLADDER CANCER. Adding durvalumab to chemotherapy extends survival in MIBC.
17. Blue light cystoscopy decreases risk of recurrence, progression in NMIBC.
18. Chemotherapy/Pembrolizumab Improves pCR in Key ER+ Breast Cancer Subgroups.
19. A Treatment Evolution Is Underway in BRAF V600E-Mutated mCRC: Investigators continue to explore new ways to manage colorectal cancer with a BRAF V600E mutation.
20. Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.
21. Paclitaxel/Ramucirumab Prolongs Survival in Gastric Cancer.
22. Perioperative Chemotherapy With FLOT Improves OS in Resectable Esophageal Cancer.
23. Evaluating the Role of Neoadjuvant Sacituzumab Govitecan in Bladder Cancer.
24. Unlocking Latest Insights Into HR-Positive, HER2-Negative Treatment Strategies.
25. Nogapendekin alfa inbakicept-pmln (N-803; Anktiva).
26. Linvoseltamab Delivers Deep, Durable Responses in R/R Multiple Myeloma.
27. Amivantamab/Chemotherapy Prolongs Progression-Free Survival in NSCLC.
28. FDA Committee Agrees That MRD Is a Viable End Point in Myeloma Trials.
29. Atara Submits BLA for Cell Therapy for Post-Transplant Complication.
30. FDA Grants Full Approval to Elahere.
31. Novel Drug Granted FDA FAST TRACK DESIGNATION.
32. Prostate cancer treatment deintensification: When less is more.
33. Pembrolizumab Combination Shows Positive OS Trend in Endometrial Cancer.
34. First-Line Durvalumab Improves PFS in Advanced Endometrial Cancer.
35. Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC.
36. Addressing irAEs Limits Interruption or Discontinuation in HCC.
37. Acalabrutinib With Axi-Cel Reveals Promising Responses in R/R B-Cell Lymphoma.
38. Survival Benefits Displayed After Stem Cell Transplant With Orca-T vs PTCy.
39. Amivantamab-vmjw (Rybrevant).
40. Ibrutinib, Venetoclax Trial Boosts PFS in MCL.
41. Lifileucel Shows Long-Term Efficacy in Melanoma.
42. Ongoing Data Support Frontline Triplet in NSCLC.
43. Trastuzumab Deruxtecan (T-Dxd; Enhertu).
44. FDA Withdraws Approval of Pepaxto in Multiple Myeloma.
45. FDA Sets Date for First-in-Class Lung Cancer Therapy.
46. FDA Approves Onivyde for First-line Metastatic Pancreatic Cancer.
47. FDA Sets Advisory Meeting for Abecma in Supplemental Multiple Myeloma Indication.
48. FDA Grants Full Approval of Balversa in Bladder Cancer.
49. Induction Chemotherapy Improves Chemoradiation Success in Locally Advanced Cervical Cancer.
50. Enfortumab Vedotin/Pembrolizumab May Be New Standard of Care in Frontline Urothelial Cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.